We have previously designed a PLGA-based NP vaccine by encapsulating a tumor Ag and α-GalCer and decorating the NPs with Abs against human CLEC9A to target cross-priming CD141+ DCs known to be capable of inducing potent CTL responses (13, 16, 26). The gene discussed is CLEC9A; the disease is neoplasm.